Recent advances of nanozyme-enhanced lateral flow assay sensing in clinic diagnosis

Nanozymes have recently garnered significant research attention in biosensing due to their unique properties, including high stability, tunable catalytic activity, and lower production costs than natural enzymes. Lateral flow assays (LFAs) are a representative point-of-care testing (POCT) technique known for their rapid and convenient detection of biological targets in complex matrices. By leveraging their exponential amplification capabilities, nanozymes have been extensively employed in LFA biosensors to enhance analytical sensitivity. This review expounds on recent advancements in nanozyme-based LFAs for clinical diagnosis. It briefly summarizes the working principle and categories of LFAs, classifies nanozymes, and discusses their diagnostic applications for various targets. Finally, the review explores the current challenges and future directions of nanozyme-based LFAs.